Do Mitogen-Activated Protein Kinase Inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by LMNA mutations?
ERK and JNK signaling inhibitors show potential for treating cardiomyopathy caused by LMNA mutations by improving heart function and preventing fibrosis.
Inhibitors of ERK and JNK signaling could potentially be used to treat humans with cardiomyopathy caused by LMNA mutations.
Wu et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: